Residency · Residency · Anesthesiology
Perioperative Acute Coronary Syndromes and Troponin Screening
Myocardial Injury After Non-Cardiac Surgery (MINS)
Definition
Myocardial injury after non-cardiac surgery (MINS) is defined as an elevated postoperative troponin attributable to myocardial ischemia rather than other causes such as pulmonary embolism, sepsis, or myocarditis. It occurs within 30 days of surgery. The critical clinical challenge is that the vast majority of episodes -- more than 80% -- are clinically silent, with no ischemic symptoms. Despite being asymptomatic, MINS is associated with a 30-day mortality of approximately 10%.
Pathophysiology -- Two Mechanisms
Perioperative myocardial injury occurs through two distinct mechanisms. Type 1 MI involves plaque rupture or erosion with thrombus formation, the classic acute coronary syndrome mechanism. Type 2 MI results from oxygen supply-demand mismatch without plaque disruption, driven by factors such as tachycardia, hypotension, anemia, and hypoxemia. Perioperative events are predominantly Type 2, accounting for an estimated 60-70% of cases.
Risk Factors
Risk factors for MINS include age above 65 years, known coronary artery disease or peripheral vascular disease, diabetes mellitus, chronic kidney disease with eGFR below 30, and elevated preoperative NT-proBNP above 300 pg/mL. Emergency and vascular surgery carry the highest procedural risk.
The VISION Study and Troponin Surveillance
Key Findings (VISION Cohort)
The VISION study was a landmark international prospective cohort that enrolled over 40,000 patients undergoing non-cardiac surgery. It found that 8% of patients had elevated postoperative high-sensitivity troponin T (hs-TnT). Even modest troponin elevations of 20-64 ng/L, just above the 99th percentile upper reference limit, were associated with an adjusted hazard ratio for death of 3.0. Peak hs-TnT values at or above 1000 ng/L carried a hazard ratio of 16.7 for 30-day mortality.
| hs-TnT Level (ng/L) | Adjusted Hazard Ratio for 30-Day Mortality | Clinical Significance |
|---|---|---|
| <14 (normal) | Reference | No myocardial injury |
| 20–64 | 3.0 | Significant prognostic impact even at modest elevation |
| 65–999 | ~10 | High risk; warrants investigation |
| ≥1000 | 16.7 | Very high mortality risk |
Troponin Screening Recommendations
The Canadian Cardiovascular Society (CCS) guidelines recommend routine postoperative troponin measurement for 48-72 hours in patients with elevated preoperative NT-proBNP (at or above 300 pg/mL), a Revised Cardiac Risk Index (RCRI) of 1 or higher, age 65 or older, or age 45-64 with significant cardiovascular disease. This recommendation is not yet universally adopted, and controversy persists regarding the appropriate clinical response to detected elevations.
<image>Flowchart illustrating the approach to postoperative troponin surveillance. Starting with preoperative risk stratification (age, RCRI, NT-proBNP), leading to decision for routine troponin monitoring at 6-12 hours and days 1-3 postoperatively, then branching into normal troponin (routine care) versus elevated troponin pathways with cardiology consultation, echocardiography, and treatment decisions.</image>
Diagnosis of Perioperative MI
Clinical Presentation
Most perioperative myocardial infarctions are clinically silent because chest pain is masked by anesthesia, analgesics, and sedation. Instead, they may present with unexplained hypotension, new arrhythmia, pulmonary edema, or hemodynamic instability. Intraoperatively, new ST-segment changes on the monitor may be the first clue.
Diagnostic Criteria (Fourth Universal Definition)
The Fourth Universal Definition of MI requires a rise and/or fall of cardiac troponin with at least one value above the 99th percentile upper reference limit, plus at least one of the following: ischemic symptoms, new ST-T changes or Q waves on ECG, imaging evidence of new loss of viable myocardium, or coronary thrombus identified on angiography or autopsy.
ECG Findings
Electrocardiographic signs of perioperative ischemia include ST depression greater than 1 mm or ST elevation in two contiguous leads, new left bundle branch block (though this is less specific than previously believed), and T-wave inversions. Continuous intraoperative ST-segment monitoring using leads II and V5 detects approximately 80% of ischemic episodes.
Echocardiography
New regional wall motion abnormalities on echocardiography are highly suggestive of acute ischemia. Global hypokinesis may indicate diffuse demand ischemia. Transesophageal echocardiography is more sensitive than transthoracic echocardiography for intraoperative detection.
Intraoperative Management of Suspected ACS
Immediate Steps
When perioperative ACS is suspected, hemodynamics should be immediately optimized: treat hypotension to maintain MAP at or above 65-70 mmHg and reduce tachycardia to below 80 bpm. Anemia should be corrected by transfusing if hemoglobin is below 8 g/dL in high-risk cardiac patients. Adequate oxygenation must be ensured. A 12-lead ECG should be obtained as soon as possible, a stat troponin drawn, and cardiology consulted.
Pharmacologic Management
Nitroglycerin is appropriate for ongoing ischemia when blood pressure is adequate. Beta-blockers, particularly esmolol, are useful for rate control in tachycardic patients but should be avoided if hypotension or acute heart failure is present. Heparin may be considered, though its use requires balancing bleeding risk against ischemic risk in consultation with the surgical team. Aspirin should be administered unless contraindicated by active surgical bleeding. Routine perioperative percutaneous coronary intervention should generally be avoided; the MANAGE trial demonstrated that conservative management is often the preferred approach.
<image>Clinical illustration showing a split-panel view: on the left, a continuous intraoperative ECG monitor displaying progressive ST depression in leads II and V5 during a non-cardiac surgical procedure. On the right, a transthoracic echocardiogram four-chamber view highlighting a new regional wall motion abnormality in the left anterior descending territory with normal surrounding wall motion.</image>
Perioperative Beta-Blocker Controversy
POISE Trial
The POISE trial randomized 8,351 patients to receive either metoprolol succinate 200 mg or placebo starting 2-4 hours before surgery. While beta-blockade reduced the rate of MI (4.2% vs. 5.7%, p=0.0017), it significantly increased mortality (3.1% vs. 2.3%, p=0.0317) and stroke (1.0% vs. 0.5%, p=0.0053). The excess harm was driven primarily by clinically significant hypotension and bradycardia.
Current Recommendations
Based on the available evidence, patients already taking beta-blockers chronically should continue them perioperatively because abrupt withdrawal increases cardiac risk. High-dose beta-blockers should not be started on the day of surgery. If perioperative beta-blockade is to be initiated, it should be started days to weeks before surgery, titrated to heart rate, and begun at low doses. The decision should be individualized based on the patient's resting heart rate and hemodynamic reserve.
DECREASE Trial Controversy
The DECREASE trial, which had previously supported aggressive perioperative beta-blockade, was investigated by Erasmus MC and found to contain fabricated data. The results were subsequently retracted from the guideline evidence base, highlighting the critical importance of evidence integrity in clinical guideline development.
Perioperative Antiplatelet Management
Patients with Coronary Stents
Patients with coronary stents require careful perioperative management of dual antiplatelet therapy (DAPT). For bare metal stents (BMS), a minimum of 4-6 weeks of DAPT is required before elective surgery. For drug-eluting stents (DES), a minimum of 6 months (ideally 12 months) of DAPT is recommended, though newer-generation DES may permit shortening to 3-6 months. Aspirin should generally be continued throughout the perioperative period. The P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) is typically held 5-7 days before surgery. Urgent surgery within the mandatory DAPT window requires a multidisciplinary discussion involving cardiology, surgery, and anesthesiology.
Bridging with IV Antiplatelet Agents
Cangrelor, an intravenous P2Y12 inhibitor with a very short half-life of approximately 3-6 minutes, may serve as a bridge during the perioperative period. Glycoprotein IIb/IIIa inhibitors such as tirofiban and eptifibatide are alternatives but carry a higher bleeding risk.
<image>Timeline diagram showing the perioperative management of dual antiplatelet therapy in patients with coronary stents. The timeline shows bare metal stent and drug-eluting stent DAPT durations, the recommended window for holding P2Y12 inhibitors preoperatively (5-7 days), continuation of aspirin throughout, and resumption of P2Y12 inhibitors postoperatively within 24-72 hours when hemostasis is achieved.</image>
Postoperative Management of MINS
When Troponin Is Elevated
An elevated postoperative troponin requires a systematic workup. Non-ischemic causes must be ruled out, including pulmonary embolism, sepsis, acute kidney injury, myocarditis, and takotsubo cardiomyopathy. Serial troponins should be drawn to establish a rise-and-fall pattern. Echocardiography is indicated if new heart failure or hemodynamic instability is present. Coronary angiography is reserved for patients with STEMI or high-risk NSTEMI features.
Medical Therapy
Aspirin should be initiated if not contraindicated, with careful bleeding risk assessment. Statin therapy should be started or intensified, as perioperative statin use is associated with reduced cardiac events. ACE inhibitors or ARBs should be considered in patients with reduced ejection fraction. The MANAGE trial demonstrated that dabigatran 110 mg twice daily reduced vascular complications after MINS without significantly increasing major bleeding, a potentially practice-changing finding that has not yet been universally adopted.
Clinical Pearls
The majority of perioperative myocardial injury is clinically silent, and without troponin screening, it will be missed entirely. Type 2 MI from supply-demand mismatch is far more common perioperatively than plaque rupture (Type 1). Abrupt cessation of chronic beta-blockers is more dangerous than the beta-blockers themselves; home beta-blocker therapy should always be continued. An elevated troponin is not always an MI -- the clinical context must be considered and alternative diagnoses investigated. Intraoperative ST monitoring with leads II and V5 provides the highest sensitivity for detecting ischemia. If a patient with a recent coronary stent requires urgent surgery, the decision to proceed is a team discussion involving cardiology, surgery, and anesthesiology.
References
- Devereaux PJ, Biccard BM, Sigamani A, et al. Association of postoperative high-sensitivity troponin levels with myocardial injury and 30-day mortality among patients undergoing noncardiac surgery. JAMA. 2017;317(16):1642-1651.
- POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial). Lancet. 2008;371(9627):1839-1847.
- Devereaux PJ, Duceppe G, Guyatt G, et al. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE). Lancet. 2018;391(10137):2325-2334.
- Duceppe G, Parlow J, MacDonald P, et al. Canadian Cardiovascular Society guidelines on perioperative cardiac risk assessment and management. Canadian Journal of Cardiology. 2017;33(1):17-32.
- Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). European Heart Journal. 2019;40(3):237-269.
